ATE196502T1 - Neue komplementations-zelllinien für defekte adenovirale vektoren - Google Patents

Neue komplementations-zelllinien für defekte adenovirale vektoren

Info

Publication number
ATE196502T1
ATE196502T1 AT98124039T AT98124039T ATE196502T1 AT E196502 T1 ATE196502 T1 AT E196502T1 AT 98124039 T AT98124039 T AT 98124039T AT 98124039 T AT98124039 T AT 98124039T AT E196502 T1 ATE196502 T1 AT E196502T1
Authority
AT
Austria
Prior art keywords
adenovirus
region
lack
derived
those
Prior art date
Application number
AT98124039T
Other languages
English (en)
Inventor
Jean-Luc Imler
Majid Mehtali
Andrea Pavirani
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9447589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE196502(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE196502T1 publication Critical patent/ATE196502T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Fuses (AREA)
  • Separation By Low-Temperature Treatments (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Thermistors And Varistors (AREA)
  • Organic Insulating Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98124039T 1993-05-28 1994-05-27 Neue komplementations-zelllinien für defekte adenovirale vektoren ATE196502T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9306482A FR2705686B1 (fr) 1993-05-28 1993-05-28 Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.

Publications (1)

Publication Number Publication Date
ATE196502T1 true ATE196502T1 (de) 2000-10-15

Family

ID=9447589

Family Applications (3)

Application Number Title Priority Date Filing Date
AT98124039T ATE196502T1 (de) 1993-05-28 1994-05-27 Neue komplementations-zelllinien für defekte adenovirale vektoren
AT98124037T ATE223968T1 (de) 1993-05-28 1994-05-27 Defekte adenoviren
AT94917063T ATE199262T1 (de) 1993-05-28 1994-05-27 Defekte adenoviren

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT98124037T ATE223968T1 (de) 1993-05-28 1994-05-27 Defekte adenoviren
AT94917063T ATE199262T1 (de) 1993-05-28 1994-05-27 Defekte adenoviren

Country Status (14)

Country Link
US (3) US6040174A (de)
EP (6) EP0652968B1 (de)
JP (2) JP4226071B2 (de)
AT (3) ATE196502T1 (de)
AU (1) AU6850394A (de)
CA (1) CA2141212C (de)
DE (4) DE69431372T2 (de)
DK (3) DK0919625T3 (de)
ES (3) ES2155090T3 (de)
FR (1) FR2705686B1 (de)
GR (2) GR3034956T3 (de)
PT (3) PT919627E (de)
SG (1) SG55199A1 (de)
WO (1) WO1994028152A1 (de)

Families Citing this family (330)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
JPH08503855A (ja) * 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
JPH09500782A (ja) * 1993-04-08 1997-01-28 ジェネティック セラピー，インコーポレイテッド 肺界面活性タンパク質をコード化するｄｎａを含むアデノウイルスベクター
US6133028A (en) * 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
ATE322547T1 (de) * 1993-06-10 2006-04-15 Genetic Therapy Inc Adenovirale vektoren für die behandlung der hämophilie
US20020136708A1 (en) 1993-06-24 2002-09-26 Graham Frank L. System for production of helper dependent adenovirus vectors based on use of endonucleases
KR100356615B1 (ko) * 1993-07-13 2003-04-03 아방티 파르마 소시에테 아노님 결함아데노바이러스벡터및유전자치료에서그의사용
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5698443A (en) * 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
ATE272113T1 (de) * 1994-02-16 2004-08-15 Crucell Holland Bv Melanoma-assoziierte antigene, epitope davon und impstoffe gegen melanoma
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
CA2189067A1 (en) * 1994-04-28 1995-11-09 Gary J. Nabel Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
ATE336587T1 (de) * 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
ATE246252T1 (de) 1994-08-16 2003-08-15 Crucell Holland Bv Von adenovirus abgeleitete rekombinante vektoren, für gentherapie
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique
FR2725726B1 (fr) * 1994-10-17 1997-01-03 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
PT787200E (pt) * 1994-10-28 2005-08-31 Univ Pennsylvania Adenovirus melhorado e metodos para a sua utilizacao
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
NZ300387A (en) * 1994-12-12 2001-07-27 Genetic Therapy Inc Adenoviral vector modified to reduce host immune and inflammatory responses and its use in gene therapy treatment
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2729674B1 (fr) * 1995-01-20 1997-04-11 Centre Nat Rech Scient Cellules pour la production d'adenovirus recombinants
FR2741891B1 (fr) * 1995-06-01 1998-01-09 Centre Nat Rech Scient Cellules pour la production d'adenovirus recombinants
FR2738575B1 (fr) * 1995-09-08 1997-10-10 Centre Nat Rech Scient Cellules pour la production d'adenovirus recombinants
FR2730411B1 (fr) * 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
FR2731710B1 (fr) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
JP3770333B2 (ja) * 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
FR2732357B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
ATE243260T1 (de) * 1995-04-17 2003-07-15 Univ Texas Adenovirus helfervirus system
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6019978A (en) 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US5698202A (en) * 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US5985846A (en) * 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
ATE445705T1 (de) * 1995-06-15 2009-10-15 Crucell Holland Bv Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
US6265212B1 (en) * 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
FR2735789B1 (fr) * 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
CZ15498A3 (cs) 1995-07-17 1998-07-15 Board Of Regents, The University Of Texas System Konstrukce pro expresi pl6 a její aplikace při léčení rakoviny
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
FR2737221B1 (fr) * 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux pour la therapie genique
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
CA2224907A1 (en) * 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
FR2737501B1 (fr) 1995-07-31 1997-10-24 Transgene Sa Nouveaux virus auxiliaires pour la preparation de vecteurs viraux recombinants
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
JP2006075171A (ja) * 1995-11-09 2006-03-23 Avigen Inc 組換えａａｖビリオン産生における使用のための補助機能
US6004797A (en) * 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
CA2177085C (en) * 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
WO1997045550A2 (en) * 1996-05-31 1997-12-04 Baxter International Inc. Mini-adenoviral vector
CZ438398A3 (cs) * 1996-07-01 1999-03-17 Rhone-Poulenc Rorer S. A. Způsob přípravy rekombinantních adenovirů
FR2750433B1 (fr) * 1996-07-01 1998-08-14 Rhone Poulenc Rorer Sa Procede de production d'adenovirus recombinants
US20040156861A1 (en) * 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
ATE291080T1 (de) 1996-12-06 2005-04-15 Aventis Pharma Inc Von humanem lipase-ähnlichem gen kodierte polypeptide, sowie zusammensetzungen und methoden
US7008776B1 (en) * 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression
FR2761689B1 (fr) 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
JP2001523103A (ja) 1997-04-28 2001-11-20 ローヌ−プーラン・ロレ・エス・アー 腫瘍治療用血管形成アンタゴニストのアデノウイルスによる腫瘍内送達
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
WO1998054345A1 (en) * 1997-05-30 1998-12-03 Baxter International Inc. Mini-adenoviral vector
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
AU752704B2 (en) * 1997-10-24 2002-09-26 Invitrogen Corporation Recombinational cloning using nucleic acids having recombination sites
US6653088B1 (en) 1997-10-24 2003-11-25 Aventis Pharma S.A. Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the β-amyloid peptide
EP1029052B1 (de) 1997-11-06 2010-08-04 Novartis Vaccines and Diagnostics S.r.l. Neisseriale antigene
US6512161B1 (en) 1998-01-08 2003-01-28 Aventis Pharmaceuticals, Inc. Transgenic rabbit that expresses a functional human lipoprotein (a)
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
EP1053317B1 (de) 1998-02-13 2006-11-02 Köster, Hubert Verwendung von ribozymen zur bestimmung der funktion von genen
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
CN100379757C (zh) 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
US6506889B1 (en) 1998-05-19 2003-01-14 University Technology Corporation Ras suppressor SUR-8 and related compositions and methods
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
CN1342206A (zh) 1998-08-28 2002-03-27 杜克大学 在IVa2,100K和/或preterminal protein序列上有缺失的腺病毒
DE19856065A1 (de) * 1998-12-04 2000-06-15 Centeon Pharma Gmbh Rekombinanter, adenoviraler Vektor mit limitierter Autoreplikationsfähigkeit in vivo
US6225113B1 (en) * 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
FR2787465A1 (fr) * 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
EP1016726A1 (de) * 1998-12-30 2000-07-05 Introgene B.V. Gentherapie zur Förderung der Angiogenesis
US6441156B1 (en) * 1998-12-30 2002-08-27 The United States Of America As Represented By The Department Of Health And Human Services Calcium channel compositions and methods of use thereof
CA2363061A1 (en) * 1999-02-18 2000-08-24 Merck & Co., Inc. Production of helper dependent adenovirus vectors based on use of endonucleases
ES2162551B1 (es) * 1999-04-09 2002-07-01 Univ Madrid Autonoma Procedimiento para la replicacion selectiva de adenovirus defectivos en celulas tumorales.
US6490775B1 (en) * 1999-04-23 2002-12-10 Veri-Tek Inc. Press operation verification system
ES2522667T3 (es) 1999-04-30 2014-11-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US7226786B2 (en) 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
FR2794771B1 (fr) * 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
WO2001002607A1 (en) * 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
CN1254719A (zh) * 1999-11-19 2000-05-31 钱其军 一种缺陷型腺病毒及其构建方法
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
JP4750999B2 (ja) 2000-03-31 2011-08-17 アベンティス・ファーマスーティカルズ・インコーポレイテツド 核因子κＢ誘導因子
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
EP1167533A1 (de) * 2000-06-23 2002-01-02 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verfahren und Mittel zur Komplementation von viraler Proteinexpression in stabilen Zelllinien
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20040101957A1 (en) * 2001-09-14 2004-05-27 Emini Emilio A. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
EP1320621A4 (de) * 2000-09-15 2005-11-23 Merck & Co Inc Verbesserte adenovirale vakzine der ersten generation zur expression codon-optimierten hiv1-gag, pol, nef und modifikationen(25.03.02)
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US6916635B2 (en) * 2000-10-02 2005-07-12 The Research Foundation Of State University Of New York Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
US7060442B2 (en) 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
JP2002142770A (ja) * 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
DK1355918T5 (da) 2000-12-28 2012-02-20 Wyeth Llc Rekombinant beskyttelsesprotein af streptococcus pneumoniae
US6614692B2 (en) 2001-01-18 2003-09-02 Saifun Semiconductors Ltd. EEPROM array and method for operation thereof
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AUPR518501A0 (en) 2001-05-22 2001-06-14 Unisearch Limited Yin yang-1
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE60228758D1 (de) 2001-12-12 2008-10-16 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
DK1497440T3 (da) 2002-04-25 2008-12-01 Crucell Holland Bv Stabile adenovirale vektorer og fremgangsmåder til propagering deraf
WO2003092738A1 (en) * 2002-04-30 2003-11-13 Dnavec Research Inc. Drug- or gene-carrier composition having lowered hemagglutinin activity
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
US20040219516A1 (en) * 2002-07-18 2004-11-04 Invitrogen Corporation Viral vectors containing recombination sites
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US20040052161A1 (en) * 2002-09-17 2004-03-18 Steven Liao Mechanical clock having wireless manipulation and adjustment function
AU2003275581A1 (en) * 2002-10-24 2004-05-13 Dnavec Research Inc. Method of transferring gene into t cells
CN1756845A (zh) 2002-11-12 2006-04-05 A·B·德塞罗斯 腺病毒载体疫苗
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EP1642966B1 (de) * 2003-06-30 2010-03-03 Dnavec Research Inc. Negativ-strang rna-virus-vektoren, welche ein gen mit veränderten hypermutierbaren regionen tragen
CN101370819A (zh) * 2003-07-02 2009-02-18 维莱尼姆公司 葡聚糖酶,编码它们的核酸以及制备和使用它们的方法
US7026164B2 (en) * 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
PT1649023E (pt) 2003-07-21 2008-11-20 Transgene Sa Polipéptido com actividade de citosina desaminase melhorada
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
WO2005051991A2 (en) 2003-11-24 2005-06-09 Sidney Kimmel Cancer Center Mucin antigen vaccine
ATE469984T1 (de) * 2003-12-01 2010-06-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
US8828957B2 (en) * 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
WO2005058369A2 (en) * 2003-12-15 2005-06-30 The University Of Iowa Research Foundation Compositions of l-caldesmon for treating viral infection
WO2005071085A1 (ja) * 2004-01-22 2005-08-04 Dnavec Research Inc. ウイルスベクターの製造方法
US7432057B2 (en) 2004-01-30 2008-10-07 Michigan State University Genetic test for PSE-susceptible turkeys
CN1922308A (zh) * 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
JP4792390B2 (ja) 2004-03-29 2011-10-12 株式会社ガルファーマ 新規ガレクチン９改変体タンパク質及びその用途
AU2005243730B2 (en) 2004-04-12 2010-05-27 Genvec, Inc. Method of using adenoviral vectors to induce an immune response
US7604798B2 (en) 2004-07-15 2009-10-20 Northwestern University Methods and compositions for importing nucleic acids into cell nuclei
EP1784416B1 (de) 2004-07-16 2011-10-05 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
CN101027662A (zh) * 2004-08-04 2007-08-29 阿菲克姆智能牧场管理系统公司 用于在限定区域内定位物体的方法和系统
US7535765B2 (en) 2004-12-09 2009-05-19 Saifun Semiconductors Ltd. Non-volatile memory device and method for reading cells
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
SG162726A1 (en) 2005-05-27 2010-07-29 San Raffaele Centro Fond Gene vector comprising mi-rna
US20060286074A1 (en) * 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
WO2007027860A2 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
US8716021B2 (en) * 2005-09-07 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
HUE028512T2 (en) * 2005-10-28 2016-12-28 Id Pharma Co Ltd Gene transfer to airway epithelial stem cell using RNA virus spike protein pseudotyped lentiviral vector
CA2628837C (en) * 2005-11-07 2018-11-27 Sidney Kimmel Cancer Center Cd40 ligand fusion protein vaccine
EP1951297A2 (de) 2005-11-10 2008-08-06 GenVec, Inc. Adenoviraler vektorbasierter impfstoff für die maul- und klauen-seuche
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
CA2659353C (en) 2006-07-28 2014-07-15 Sanofi-Aventis Composition and method for treatment of tumors
WO2008060814A2 (en) 2006-10-19 2008-05-22 Merck & Co., Inc. ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF
AU2007319604B2 (en) 2006-10-19 2011-03-24 Csl Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US8420103B2 (en) 2007-01-30 2013-04-16 Transgene S.A. Papillomavirus vaccines
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
ES2337973B8 (es) 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
NZ592368A (en) 2008-11-05 2013-11-29 Wyeth Llc Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
JP2012515146A (ja) 2009-01-13 2012-07-05 トランジェーヌ、ソシエテ、アノニム 免疫刺激のためのサッカロマイセス・セレビシエのミトコンドリア核酸画分の使用
DK2382474T3 (en) 2009-01-20 2015-04-07 Transgene Sa SOLUBLE ICAM-1 as a biomarker FOR PREDICTION OF THERAPEUTIC RESPONSE
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
MX2011010061A (es) 2009-03-24 2011-11-18 Transgene Sa Biomarcador para monitorear pacientes.
EP2419728B1 (de) 2009-04-17 2014-01-08 Transgene SA Biomarker für patientenüberwachung
AU2010270313B2 (en) 2009-07-10 2014-05-22 Transgene Sa Biomarker for selecting patients and related methods
KR20120052352A (ko) 2009-08-07 2012-05-23 트랜스진 에스.에이. Ｈｂｖ 감염을 치료하는 조성물
CN102791852B (zh) 2009-10-15 2014-05-07 克鲁塞尔荷兰公司 纯化腺病毒颗粒的方法
KR101805938B1 (ko) 2009-10-15 2018-01-10 얀센 백신스 앤드 프리벤션 비.브이. 고밀도 세포 배양액에서 아데노바이러스의 정제 방법
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
EA201270607A1 (ru) 2009-11-09 2012-09-28 Генвек, Инк. Аденовирус обезьян и способы его использования
EP2536829B1 (de) 2010-02-15 2016-04-06 Crucell Holland B.V. Verfahren zur Herstellung von adenoviralen Ad26-Vektoren
US9682133B2 (en) 2010-03-17 2017-06-20 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
PL3831406T3 (pl) 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
EP2618838A1 (de) 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutische impfung gegen aktive tuberkulose
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
WO2012088041A1 (en) 2010-12-20 2012-06-28 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
EP2674491B1 (de) 2011-02-08 2017-06-14 Mie University Verfahren zur erzeugung eines virusvektors für einen gentransfer
JPWO2012147370A1 (ja) * 2011-04-28 2014-07-28 国立大学法人山口大学 ターミネータ配列を含む高発現用リバースプライマー及びリニアｄｎａ
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
US9629906B2 (en) 2011-10-05 2017-04-25 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
JP6757121B2 (ja) 2011-10-05 2020-09-16 ジェンヴェック エルエルシー シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法
IN2014DN03005A (de) 2011-10-05 2015-05-08 Genvec Inc
EP2764011B1 (de) 2011-10-05 2021-04-07 GenVec, Inc. Auf adenovirenvektoren-basierender impfstoff gegen das respiratorische synzytialvirus (rsv)
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
WO2013116591A1 (en) 2012-02-02 2013-08-08 Genvec, Inc. Adenoviral vector-based malaria vaccine
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CA2864956C (en) 2012-03-12 2021-11-09 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
AP2014007993A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
EP2855511B1 (de) 2012-05-29 2019-07-24 GenVec, Inc. Impfstoff gegen das herpes-simplex virus
EP2855669B1 (de) 2012-05-29 2018-10-10 GenVec, Inc. Modifizierte serotyp-28-adenovirusvektoren
CA2878800A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
WO2014164703A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
CN105473604B (zh) 2013-03-13 2021-01-22 美国政府(由卫生和人类服务部的部长所代表) 融合前rsv f蛋白和其用途
CN110590916A (zh) 2013-04-25 2019-12-20 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
KR102313153B1 (ko) 2013-06-17 2021-10-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
EP4098276A1 (de) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis-zusammensetzungen und verfahren dafür
TR201900274T4 (tr) 2013-09-19 2019-02-21 Janssen Vaccines & Prevention Bv Geliştirilmiş adenovirüs formülasyonları.
RU2695462C2 (ru) 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
EP3107939B1 (de) 2014-02-19 2020-06-17 University of Florida Research Foundation, Inc. Abgabe einer nrf2-therapie zum schutz gegen reaktive sauerstoffspezies
WO2016037154A1 (en) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
JP6325751B2 (ja) 2014-11-04 2018-05-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１６ワクチン
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
EP3236998A1 (de) 2014-12-24 2017-11-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Rekombinante metapneumovirusproteine und deren verwendung
WO2016118642A1 (en) 2015-01-20 2016-07-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof
EP3256156B1 (de) 2015-02-13 2025-02-12 Transgene Immunotherapeutischer impfstoff und antikörperkombinationstherapie
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
KR20170140180A (ko) 2015-02-24 2017-12-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
DK3271729T3 (da) 2015-03-18 2020-12-14 Janssen Vaccines & Prevention Bv Analyser til rekombinante ekspressionssystemer
EP3280425B1 (de) 2015-04-07 2022-06-01 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Verfahren zur induzierung von zellteilung von postmitotischen zellen
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
JP7189014B2 (ja) 2015-07-07 2022-12-13 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
AU2016309743B2 (en) 2015-08-20 2019-02-07 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
BR112018006488B1 (pt) 2015-10-06 2024-03-12 Janssen Vaccines & Prevention B.V. Métodos para prevenir a degradação induzida por plástico de biológicos
WO2017139392A1 (en) 2016-02-08 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant hiv-1 envelope proteins and their use
US10808011B2 (en) 2016-03-09 2020-10-20 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant HIV-1 envelope proteins and their use
KR20220041966A (ko) 2016-04-05 2022-04-01 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 용해성 융합-전 rsv f 단백질
BR112018070323A2 (pt) 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv vacina contra rsv
US10517944B2 (en) 2016-05-02 2019-12-31 Janssen Vaccines & Prevention B.V. Therapeutic HPV vaccine combinations
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2017194655A1 (en) 2016-05-12 2017-11-16 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
EP3472327B1 (de) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potenter und ausbalancierter bidirektionaler promotor
EP3484506A1 (de) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv-impfstoffe
US11155832B2 (en) 2016-09-30 2021-10-26 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into T cells
EP3518968B1 (de) 2016-10-03 2022-01-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hiv-1-env-fusionspeptid-immunogene und deren verwendung
EP3522920A2 (de) 2016-10-10 2019-08-14 Transgene SA Immuntherapeutisches produkt und mdsc-modulator-kombinationstherapie
WO2018081318A1 (en) 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
JP7078620B2 (ja) 2016-11-16 2022-05-31 イミュノミック セラピューティックス， インコーポレイテッド アレルギーの治療のための核酸
EP3554538A2 (de) 2016-12-16 2019-10-23 Institute for Research in Biomedicine Neuartige rekombinante rsv-f-präfusionsproteine und verwendungen davon
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
CN110268061B (zh) 2017-02-09 2024-07-16 扬森疫苗与预防公司 用于表达异源基因的有效的短启动子
EP3600405B1 (de) 2017-03-24 2025-08-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Glycanmaskierte manipulierte äussere domänen von hiv-1 gp120 und deren verwendung
EP4512477A3 (de) 2017-04-22 2025-06-11 Immunomic Therapeutics, Inc. Verbesserte lampenkonstruktionen
CN110913892A (zh) 2017-05-02 2020-03-24 免疫治疗有限公司 包含癌抗原的lamp(溶酶体相关膜蛋白)构建物
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
EP3697440A1 (de) 2017-10-16 2020-08-26 The United States of America, as represented by the Secretary, Department of Health and Human Services Rekombinante hiv-1-hüllproteine und deren verwendung
KR20200077559A (ko) 2017-10-31 2020-06-30 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 및 이의 용도
JP7438943B2 (ja) 2017-10-31 2024-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルス及びその用途
EP3704138A1 (de) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention B.V. Adenovirus und verwendungen davon
JP7229239B2 (ja) 2017-10-31 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルスベクター及びその用途
CA3081436A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
RS63526B1 (sr) 2018-01-23 2022-09-30 Janssen Vaccines & Prevention Bv Vakcine za virus gripa i njihove upotrebe
JP7581048B2 (ja) 2018-03-06 2024-11-12 プレシゲン，インコーポレイテッド ヒトパピローマウイルスワクチンおよびその使用
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
CA3100004A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
US20210254103A1 (en) 2018-07-02 2021-08-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
US20210361318A1 (en) 2018-07-02 2021-11-25 Voyager Therapeutics, Inc. Cannula system and use thereof
CA3113648A1 (en) 2018-09-21 2020-03-26 University Of Connecticut Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome
EP3870703A1 (de) 2018-10-22 2021-09-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Rekombinantes gp120-protein mit v1-schleifendeletion
JOP20210106A1 (ar) 2018-11-13 2023-01-30 Janssen Vaccines And Prevention B V بروتينات rsv f سابقة الاندماج مستقرة
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
MX2021012991A (es) 2019-04-25 2021-12-10 Janssen Vaccines & Prevention Bv Antigenos de gripe recombinantes.
KR20220008816A (ko) 2019-05-15 2022-01-21 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 기반 백신을 사용한 호흡기 세포융합 바이러스 감염의 예방적 치료
BR112021022087A2 (pt) 2019-05-15 2021-12-28 Janssen Vaccines & Prevention Bv Coadministração de vacina sazonal contra influenza e vacina contra vírus respiratório sincicial à base de adenovírus
MX2022002766A (es) 2019-09-05 2022-04-06 Janssen Vaccines & Prevention Bv Vacunas contra el virus de la gripe y usos de las mismas.
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN114710957B (zh) 2019-10-03 2025-08-19 扬森疫苗与预防公司 腺病毒载体及其用途
WO2021072129A2 (en) 2019-10-08 2021-04-15 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
WO2021077051A1 (en) 2019-10-18 2021-04-22 Immunomic Therapeutics, Inc Improved lamp constructs comprising cancer antigens
AU2020385683A1 (en) 2019-11-18 2022-06-30 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
JP2023513693A (ja) 2020-02-11 2023-04-03 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ＳＡＲＳ－ＣｏＶ－２ワクチン
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
US11213482B1 (en) 2020-03-05 2022-01-04 University of Pittsburgh—Of the Commonwealth System of Higher Educat SARS-CoV-2 subunit vaccine and microneedle array delivery system
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
US11773391B2 (en) 2020-04-01 2023-10-03 University of Pittsburgh—of the Commonwealth System of Higher Education Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
JP2023521194A (ja) 2020-04-13 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用
EP4142785A2 (de) 2020-04-29 2023-03-08 The United States of America, as represented by the Secretary, Department of Health and Human Services Rekombinante menschliche metapneumovirus f proteine und deren verwendung
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4178605A1 (de) 2020-07-13 2023-05-17 Transgene Behandlung von immundepression
WO2022035860A2 (en) 2020-08-10 2022-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Replication-competent adenovirus type 4-hiv env vaccines and their use
TW202227621A (zh) 2020-11-19 2022-07-16 美商凱立凡爾免疫治療股份有限公司 重塑腫瘤微環境的溶瘤免疫療法
WO2022232648A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion-stabilized lassa virus glycoprotein complex and its use
MX2023012608A (es) 2021-04-30 2023-11-03 Kalivir Immunotherapeutics Inc Virus oncoliticos para la expresion modificada del mhc.
AU2022323509A1 (en) 2021-08-03 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
CA3234809A1 (en) 2021-10-20 2023-04-27 Steven Goldman Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
EP4426331A1 (de) 2021-11-02 2024-09-11 University of Rochester Tcf7l2-vermittelte remyelinisierung im gehirn
US20250018060A1 (en) 2021-11-19 2025-01-16 Christiana Care Gene Editing Institute, Inc. Adenovirus delivery system for cancer treatment
US20250197455A1 (en) 2022-03-27 2025-06-19 TThe United States of America, as represented by the Secretary, Department of Health and Human Servi Base-covered hiv-1 envelope ectodomains and their use
WO2023196898A1 (en) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta globin mimetic peptides and their use
EP4508071A1 (de) 2022-04-10 2025-02-19 Immunomic Therapeutics, Inc. Bicistronische lampenkonstrukte mit immunreaktionserhöhenden genen und verfahren zur verwendung davon
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
EP4338727A1 (de) 2022-09-14 2024-03-20 Roquette Freres Adenovirus-formulierungen
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
EP4658294A2 (de) 2023-02-02 2025-12-10 University of Rochester Kompetitiver ersatz von gliazellen
WO2024249626A1 (en) 2023-05-30 2024-12-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 envelope triple tandem trimers and their use
WO2025090427A1 (en) 2023-10-23 2025-05-01 University Of Rochester Glial-targeted relief of hyperexcitability in neurodegenerative diseases
WO2025158316A1 (en) 2024-01-26 2025-07-31 Janssen Biotech, Inc. Ovarian neoantigens and use thereof
WO2026030724A1 (en) 2024-08-01 2026-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sars-cov-2 vaccine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
GB9001766D0 (en) * 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
GB9114437D0 (en) * 1991-07-03 1991-08-21 Health Lab Service Board Recombinant adenoviruses and the use thereof for detecting the presence in eukaryotic cells of the expression products of specific genes
US6099831A (en) 1992-09-25 2000-08-08 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
CA2145535C (en) * 1992-09-25 2007-07-17 Axel Kahn Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
AU694097B2 (en) * 1992-11-18 1998-07-16 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
JPH08503855A (ja) * 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
JPH09500782A (ja) * 1993-04-08 1997-01-28 ジェネティック セラピー，インコーポレイテッド 肺界面活性タンパク質をコード化するｄｎａを含むアデノウイルスベクター
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
AU6829994A (en) * 1993-05-10 1994-12-12 Regents Of The University Of Michigan, The Gene transfer into pancreatic and biliary epithelial cells
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
ATE322547T1 (de) * 1993-06-10 2006-04-15 Genetic Therapy Inc Adenovirale vektoren für die behandlung der hämophilie
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
JP3770333B2 (ja) * 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
ATE445705T1 (de) * 1995-06-15 2009-10-15 Crucell Holland Bv Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5981275A (en) 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors

Also Published As

Publication number Publication date
EP0919624A3 (de) 1999-08-18
GR3034956T3 (en) 2001-02-28
EP0919627B1 (de) 2000-09-20
FR2705686A1 (fr) 1994-12-02
EP0919625A2 (de) 1999-06-02
DK0919627T4 (da) 2007-06-25
PT919627E (pt) 2000-12-29
ES2182212T3 (es) 2003-03-01
EP0652968A1 (de) 1995-05-17
JP5410721B2 (ja) 2014-02-05
CA2141212C (fr) 2007-04-17
SG55199A1 (en) 1998-12-21
DK0919627T3 (da) 2001-01-22
US6040174A (en) 2000-03-21
US7005277B2 (en) 2006-02-28
JP2009050267A (ja) 2009-03-12
EP0919627A3 (de) 1999-07-28
DK0919625T3 (da) 2002-12-30
DE69426722T2 (de) 2001-09-20
DE69425989T3 (de) 2007-10-18
ATE223968T1 (de) 2002-09-15
PT652968E (pt) 2001-07-31
DK0652968T3 (da) 2001-06-11
EP0919625B1 (de) 2002-09-11
US20030170885A1 (en) 2003-09-11
GR3035841T3 (en) 2001-08-31
ATE199262T1 (de) 2001-03-15
CA2141212A1 (fr) 1994-12-08
DE69425989T2 (de) 2001-02-22
DE69426722D1 (de) 2001-03-29
EP0919627B2 (de) 2007-03-14
EP1149916A3 (de) 2007-08-29
DE69431372T2 (de) 2003-07-31
FR2705686B1 (fr) 1995-08-18
JP4226071B2 (ja) 2009-02-18
EP0919626A3 (de) 1999-08-18
DE919627T1 (de) 2000-04-20
JPH07509616A (ja) 1995-10-26
US20010049136A1 (en) 2001-12-06
EP0919624A2 (de) 1999-06-02
EP1149916A2 (de) 2001-10-31
ES2155090T3 (es) 2001-05-01
ES2151310T3 (es) 2000-12-16
US7067309B2 (en) 2006-06-27
WO1994028152A1 (fr) 1994-12-08
EP0919627A2 (de) 1999-06-02
EP0652968B1 (de) 2001-02-21
AU6850394A (en) 1994-12-20
PT919625E (pt) 2002-11-29
EP0919626A2 (de) 1999-06-02
EP0919625A3 (de) 1999-08-18
DE69431372D1 (de) 2002-10-17
ES2151310T5 (es) 2007-10-16
DE69425989D1 (de) 2000-10-26

Similar Documents

Publication Publication Date Title
DE69425989D1 (de) Neue Komplementations-Zelllinien für defekte adenovirale Vektoren
Schiedner et al. Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production
Hardy et al. Construction of adenovirus vectors through Cre-lox recombination
NO20045131L (no) Stabile adenovirale vektorer samt fremgangsmater ved formering derav
Zhou et al. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted
ATE466931T1 (de) Verbesserte adenovirusvektoren
WO2005001103A3 (en) Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
IS4754A (is) Genaferjur og aðferðir fyrir genaflutning inn í frumur
CA2428739A1 (en) Complementing cell lines
Wang et al. Adenovirus technology for gene manipulation and functional studies
CA2161962A1 (en) Adenovirus vectors for gene therapy
AU4716399A (en) Replication-defective recombinant adenovirus with mutated major late promoter
CA2477954A1 (en) Means and methods for the production of adenovirus vectors
Lusky et al. Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3
CA2378586A1 (en) Replication-competent anti-cancer vectors
CA2226833A1 (en) Adenovirus vectors for gene therapy
Van Ormondt et al. Comparison of the nucleotide sequences of early region Elb DNA of human adenovirus types 12, 7 and 5 (subgroups A, B and C)
DK1071805T3 (da) Adenovirusvektorer til sygdomsbehandling
Cao et al. The ORF RTL1 transcript of fowl adenovirus type-8 is spliced and truncated at late stages of the virus replication cycle
CA2522624A1 (en) Novel cosmid vector

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0919627

Country of ref document: EP